Footnotes

• JB-W and JA are joint first authors.

• Twitter @johanne_brooks, @James_Ashton, @anjan_dhar6, @samiHoque2, @barrettsonline

• Contributors JB-W organised the authors, did the literature review wrote and edited the manuscript. JA did the literature review, wrote the manuscript and designed all the figures. AD wrote the manuscript and edited the manuscript. TT did the literature review and reviewed the manuscript for content and edited. PBA reviewed the manuscript for content and edited. SH reviewed the manuscript for content and edited. LBL wrote the manuscript and provided significant editing input. SS wrote the manuscript and provided significant editing input.

• Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

• Competing interests COIs: JB-W holds research grants from AbbVie, and has received speaker fees from Dr Falk Pharma. JA no COI to declareAD Advisory and consultancy for Pfizer UK, Tillotts Pharma UK, Dr Falk Pharma, Pharmacosmos, Takeda UK, Honoraria and Speaker Fees from Dr Falk Pharma, Pfizer, Janssen, Tillotts Pharma, Pharmacosmos, Takeda UKPBA received research grants from Pfizer and speaker fees from Takaeda, AbbVie, GSK, Janssen, MSD and Tillotts. TT no COI to declare. SH no COI to declare. LBL is a minor shareholder in Odin Vision since 2018SS holds research grants from Biogen, Takeda, AbbVie, Tillotts Pharma, Ferring and Biohit; served on the advisory boards of Takeda, AbbVie, Merck, Ferring, Pharmacocosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Celgene and Tillotts Pharma; and has received speaker fees from AbbVie, Biogen, AbbVie, Janssen, Merck, Warner Chilcott and Falk Pharma.

• Provenance and peer review Not commissioned; externally peer reviewed.